Seek: Result 2016
Seek's 2016 result was a re-run of the February interim. Early stage ventures will need to be watched but the result certainly justified last year's Buy recommendation.
Virtus Health: Result 2016
Virtus has reported a bumper year of growth, but pricing pressures are beginning to mount at its budget clinics.
Amaysim: Result 2016
After a poor interim result, amaysim needed a stunner to impress. We got it and it did.
ASX cut to Hold
With it's price rising following last week's full-year result, we're downgrading ASX to Hold.
Medibank & NIB: Result 2016
Medibank continues to lose customers to its smaller rival, with growth and margins going in the wrong direction.
IAG: Result 2016
Low growth has become the norm, but higher margins and a share buyback provided rays of light in this insurer's 2016 result.
Trade Me: Result 2016
Trade Me's result showed this company is no sloth. Past investments in the cost base mean profit growth is about to accelerate.
ASX: Result 2016
A fourth-quarter surge in futures volumes and large capital raisings from the big banks have helped ASX to an impressive result.
SomnoMed: Result 2016
It's been another year of impressive growth for this maker of sleep apnea mouthguards.
Crown Resorts: Result 2016
Macau may be bottoming while Crown's Australian resorts continue to pump out cash.
Sonic Healthcare: Result 2016
Strong growth in Australia and the UK produced a record profit for this pathology operator.
Sydney Airport: Interim result 2016
Australia's gateway airport is enjoying a bumper year, with international traffic particularly strong.
Nanosonics: Result 2016
Nanosonics continues to fire on all cylinders but it isn't without its risks.
QBE: Interim result 2016
Lower interest rates and a rough patch for QBE's Australian business have led to lower profits for the insurer.
InvoCare: Interim result 2016
A downturn in the death rate and minor market share losses spooked the market, but both should prove temporary.
BHP Billiton: Result 2016
This result illustrates a longstanding truth about BHP: great assets, poor allocation.
CSL: Result 2016
The new flu vaccine business isn't yet profitable, but antibodies are flying off the shelves.
The Thorn identity
After sailing through a regulatory storm, an opportunity may present to buy Thorn Group, the consumer leasing leader.
iCar Asia under review
A reassessment means we're removing our positive view until after iCar Asia's interim result is released.
F&P Healthcare sues ResMed
F&P Healthcare is taking larger rival ResMed to court for patent infringement.
Ansell: Result 2016
A recovering Russian economy and the potential sale of Ansell's condom business made this a result to remember.
REA Group: Result 2016
REA Group might see its future overseas, but this result was all about the excellent performance of the flagship Australian division.
Magellan Financial Group: Result 2016
Retail investors have given Magellan a boost with fund inflows of $2.3 billion in 2016.
Call 1300 880 160
Start a chat
Schedule a call
